Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 3:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 690 matching trials from the live ClinicalTrials.gov search.
Conditions
Core Binding Factor Alpha Subunits, Hematologic Neoplasms, Leukemia, Lymphoma
Interventions
Cyclophosphamide, Busulfan, Fludarabine, Total Body Irradiation, Hematopoietic stem cells, Tacrolimus, Mycophenolate Mofetil
Drug · Radiation · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
4 Years to 70 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Resistance Training, Colon Cancer, Chemotherapy Effect
Interventions
Resistance training
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Oakland, California • Boston, Massachusetts • Hershey, Pennsylvania
Conditions
Primary Myelofibrosis, Secondary Myelofibrosis
Interventions
Cyclophosphamide, JAK Inhibitor, Fludarabine, Recombinant Granulocyte Colony-Stimulating Factor, Melphalan, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Tacrolimus, Total-Body Irradiation, Computed Tomography, Magnetic Resonance Imaging, Bone Marrow Biopsy, Bone Marrow Aspiration, Biospecimen Collection, Echocardiography Test, Multigated Acquisition Scan
Drug · Biological · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Lymphoma, Myeloma, Leukemia, Myelodysplasia, Solid Tumors, Hodgkin's Disease, Myelofibrosis
Interventions
Total Body Irradiation with Fludarabine in UCB Transplants
Procedure
Lead sponsor
Duke University
Other
Eligibility
14 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Gene Mutations, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Therapy-Related Acute Myeloid Leukemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Bone Marrow Transplantation, Cyclophosphamide, Fludarabine, Laboratory Biomarker Analysis, Melphalan, Mycophenolate Mofetil, Natural Killer Cell Therapy, Peripheral Blood Stem Cell Transplantation, Tacrolimus, Total-Body Irradiation
Procedure · Drug · Other + 2 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
2 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Houston, Texas
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Impact of Aerobic Exercise on Pain Modulation in Healthy Adults

NCT07083219
Conditions
Healthy Adult
Interventions
Aerobic High Intensity Interval Training
Behavioral
Lead sponsor
University of Texas, El Paso
Other
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
El Paso, Texas
Conditions
Obesity, Insulin Resistance
Interventions
high-intensity interval training
Other
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Albuquerque, New Mexico
Conditions
Type 2 Diabetes, Insulin Sensitivity/Resistance, Cognition, Brain Blood Flow
Interventions
Intranasal Insulin, Intranasal Placebo, High Intensity Exercise
Drug · Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
55 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
New Brunswick, New Jersey • Piscataway, New Jersey
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cyclophosphamide, fludarabine phosphate, NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL, dendritic cell vaccine therapy, aldesleukin, fludeoxyglucose F 18, positron emission tomography, laboratory biomarker analysis
Drug · Biological · Radiation + 2 more
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
16 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Liver Transplantation, Immune Tolerance, Immune Tolerance/Drug Effects, Graft Survival, Hematopoietic Stem Cell, Chimerism, Immunosuppression After Liver Transplantation, Immunosuppression Disorders, End Stage Liver Disease
Interventions
Donor Hematopoietic Stem and Progenitor Cell Infusion
Biological
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Los Angeles, California
Terminated Phase 2Phase 3 Interventional Results available

Cardiac Safe Transplants for Systemic Sclerosis

NCT03593902
Conditions
Systemic Sclerosis, Scleroderma
Interventions
Rituximab, Fludarabine, Cyclophosphamide, Mesna, rATG, Methylprednisolone, G-CSF, IVIg, Autologous Stem Cells
Drug · Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Chicago, Illinois
Conditions
Multiple Myeloma
Interventions
Thalidomide, Ara-C, BCNU, Cisplatin, Cytoxan, Dexamethasone, Doxorubicin, Etoposide, Filgrastim, Recombinant GM-CSF, Interferon-alpha-2b, Melphalan, Vincristine
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Enrollment
668 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2014
U.S. locations
1
States / cities
Little Rock, Arkansas
Conditions
Lymphoma, Non-Hodgkin
Interventions
Hematopoietic Stem Cell Transplant
Biological
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
1 Year to 75 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
21
States / cities
Duarte, California • La Jolla, California • Sacramento, California + 17 more
Conditions
ACL, Opioid Use, Cryotherapy Effect, Vibration; Exposure, Pain, Postoperative
Interventions
VibraCool mechanical stimulation and neuromodulatory therapeutic device, Cryocompression (Game Ready, Bregs) device, Standard ice packs
Device
Lead sponsor
Columbia University
Other
Eligibility
Not listed
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
New York, New York
Completed Not applicable Interventional Accepts healthy volunteers Results available

Identifying Therapeutic Targets of Accelerated Sarcopenia

NCT03118050
Conditions
Sarcopenia, Diabetes Mellitus, Aging
Interventions
Resistance exercise training, Bed rest, Intensive physical therapy
Behavioral
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
60 Years to 85 Years
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Galveston, Texas
Conditions
Lymphoma, Multiple Myeloma, Leukemia, Myelodysplastic Syndrome
Interventions
Busulfan, Fludarabine, Cytoxan
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
Up to 65 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
Baltimore, Maryland • Houston, Texas • Seattle, Washington
Conditions
Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Myelodysplasia
Interventions
Unmanipulated UCB, SR-1 UCB
Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
2 Years to 35 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Acute Myeloid Leukemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Clofarabine, Cyclosporine, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Pharmacological Study, Total-Body Irradiation
Procedure · Drug · Other + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
2 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
4
States / cities
Aurora, Colorado • New Orleans, Louisiana • Seattle, Washington
Conditions
Granulomatous Disease, Chronic, X-linked
Interventions
Lentiviral G1XCGD Gene Therapy
Biological
Lead sponsor
University of California, Los Angeles
Other
Eligibility
23 Months and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
3
States / cities
Los Angeles, California • Bethesda, Maryland • Boston, Massachusetts
Conditions
Multiple Sclerosis
Interventions
Hematopoietic Stem Cell Therapy, Standard treatment with a conventional drug
Procedure · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 55 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Myelodysplastic Syndrome (MDS), Chronic Lymphocytic Leukemia (CLL), Chemotherapy-sensitive Lymphoma, Acute Lymphoblastic Leukemia (ALL)/T Lymphoblastic Lymphoma, Acute Myelogenous Leukemia (AML), Acute Biphenotypic Leukemia (ABL), Acute Undifferentiated Leukemia (AUL)
Interventions
Fludarabine, Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5, Total Body Irradiation (TBI) 200cGy on Day -1, Infusion of non-T-cell depleted bone marrow on Day 0, Busulfan, Cyclophosphamide 50mg/kg/day IV on Days -2,-1, Cyclophosphamide 50mg/kg/day IV on Days -5,-4, Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1, Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4, Sirolimus, Mycophenolate mofetil, G-CSF, Pre-HCT Mesna on Days -6 and -5, Pre-HCT Mesna on Days -2 and -1, Pre-HCT Mesna on Days -5 and -4, Post-HCT Mesna
Drug · Radiation · Procedure
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
15 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
11
States / cities
Gainesville, Florida • Miami, Florida • Tampa, Florida + 7 more
Recruiting Not applicable Interventional Accepts healthy volunteers

Optimizing an Extended Care Intervention to Promote Weight Loss Maintenance

NCT06785064
Conditions
Obesity Prevention, Weight Change, Weight Loss, Weight Loss Maintenance
Interventions
Reduced Food Variety (RFV), Home-based Resistance Training (HBRT), Buddy Training and Support (BTS), Acceptance and Commitment (ACT) Workshops
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
544 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
High Risk Myeloid Malignancies, Cord Blood Transplant
Interventions
ECT-001-CB (UM171-Expanded Cord Blood Transplant)
Biological
Lead sponsor
ExCellThera inc.
Industry
Eligibility
0 Years to 21 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
New York, New York
Conditions
Systemic Scleroderma, Severe Systemic Sclerosis
Interventions
fludarabine phosphate, Mycophenolic Acid, tacrolimus, total-body irradiation, bone marrow transplantation, reduced intensity allogeneic hematopoietic stem cell transplantation, quality-of-life assessment, laboratory biomarker analysis, flow cytometry, biopsy
Drug · Radiation · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
2
States / cities
Denver, Colorado • Seattle, Washington